How AstraZeneca's latest vaccine troubles could slow the global recovery

European drug regulators confirmed a link between the Oxford-AstraZeneca Covid-19 shot and rare blood clots on Wednesday, but stopped short of recommending its use be limited. UK authorities recommended that people under 30 take alternative vaccines.

Posted: Apr 8, 2021 1:54 PM
Updated: Apr 8, 2021 1:59 PM

AstraZeneca's vaccine is key to ending the global economic slump caused by the coronavirus. But a series of missteps by the drugmaker and new concerns over blood clots risk undermining public confidence in the shot and delaying the recovery.

European drug regulators confirmed a link between the Oxford-AstraZeneca Covid-19 shot and rare blood clots on Wednesday, but stopped short of recommending its use be limited. UK authorities recommended that people under 30 take alternative vaccines.


FOX 55: Tracking the COVID-19 Vaccine

It's the latest setback for AstraZeneca, which has faced criticism over its communication with the public and regulators, the design of its vaccine trials and severe production delays that have slowed the rollout of shots in Europe.

Authorities maintain that the benefits of the vaccine far outweigh the risks for most age groups. Yet shifting guidance and blood clot worries risk snarling distribution efforts in many countries. Germany suspended the use of the AstraZeneca vaccine last week in people under 60 years old, while Australia said Thursday it will not give it to people under the age of 50.

The safety questions could have even bigger implications for developing and middle-income countries, many of which are relying on the shot to unlock their economic comebacks because it's cheaper than other vaccines and can be stored more easily. Many are accessing it through Covax, a global vaccine-sharing program, which has secured more than half its supply from AstraZeneca as of March.

Overall, orders for an estimated 2.4 billion doses of AstraZeneca's vaccine have been confirmed, according to the Duke Global Health Innovation Center. That's roughly 28% of the global total.

"There's a lot of uncertainty here," said Ben May, director of macro research at Oxford Economics. He said the AstraZeneca developments weren't enough to revise near-term growth forecasts, but that he would keep monitoring the situation closely.

The World Health Organization said in a statement Wednesday that "based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed."

AstraZeneca said that nearly 200 million people around the world have already received its vaccine, and that reviews by EU and UK regulators "reaffirmed the vaccine offers a high-level of protection against all severities of Covid-19 and that these benefits continue to far outweigh the risks."

A rough start

AstraZeneca received emergency use authorization from the United Kingdom in late December and the European Union one month later. Because the vaccine was less expensive and could be stored at higher temperatures than ones developed by Pfizer and Moderna, it was heralded as a breakthrough, particularly for less affluent countries that lack sophisticated logistics networks.

The company also generated lots of goodwill by pledging to supply its vaccine at no profit during the pandemic, and by partnering with the Serum Institute of India, which agreed to produce more than 1 billion doses for low and middle-income countries. AstraZeneca has already provided over 30 million doses to more than 58 countries through Covax.

However, a series of missteps generated a string of bad headlines for the Anglo-Swedish drugmaker.

The first issue cropped up in November, when the company faced questions about data from large-scale trials. Volunteers received different doses due to a manufacturing error, creating confusion about its actual effectiveness.

AstraZeneca did not mention that a mistake caused the dosing discrepancy in its initial announcement, generating concerns about a lack of transparency.

"I hate to criticize fellow academics, or anyone for that matter, but releasing information like this is like asking us to try and read the tea leaves," Dr. Saad Omer, a vaccine specialist at the Yale School of Medicine, said at the time.

More stumbles followed. Germany's vaccine commission said in January that AstraZeneca's shots shouldn't be given to people older than 65, citing insufficient data for the age group. France also initially limited AstraZeneca vaccines to those under 65. Both countries changed course last month.

Jeffrey Lazarus, head of the health systems research group at the Barcelona Institute for Global Health, previously told CNN Business this was an "easily avoidable" issue tied to trial design.

Had the vaccine rollout been smooth, such stumbles may have been forgotten. But continued shortfalls in supply of the AstraZeneca shots in Europe, which is now mired in a third wave of coronavirus infections, have triggered huge political blowback in the bloc. Leaders have imposed restrictions on vaccine exports.

"If we had received the 100% of AstraZeneca's vaccines that were contracted to us, the European Union would be at the same level today as Great Britain in terms of vaccines," European Commissioner Thierry Breton said in a recent interview with Le Parisien newspaper. "So I can say that the pocket of turbulence we have experienced is solely due to AstraZeneca's failure to deliver."

AstraZeneca's future role

The company also ran afoul of US regulators last month when it submitted trial data from the country. The US National Institute of Allergy and Infectious Diseases expressed concerns that the efficacy information submitted was "outdated." AstraZeneca quickly sent in revised data, but Dr. Anthony Fauci, the agency's director, called it "an unforced error."

Now, as fears about rare blood clots force governments around the world to reassess the risk-benefit analysis of providing shots to all age groups, the United States has indicated it does not need AstraZeneca's doses.

"We have enough very good vaccines," Fauci, who also serves as chief medical adviser to President Joe Biden, told CNN on Wednesday.

Not all countries will have that luxury, however. India, for example, is leaning heavily on AstraZeneca's shot as it tries to fight back against an alarming spike in cases.

Lazarus said Thursday that if wealthier nations decide they want to reduce their reliance on AstraZeneca, he hopes shots can be sent to other nations in need, since the data still indicates it's safe and effective.

"There are plenty of other countries that don't have other options because of the logistics ... and because of the cost," he said.

He does worry, however, that all the bad publicity could affect people's willingness to accept an AstraZeneca vaccine when it becomes available.

"This is definitely going to impact the reputation of the AstraZeneca vaccine," Lazarus said. "[It] will lead to lower uptake."

That could be bad news for the global economic recovery. This week, the International Monetary Fund upgraded its forecast for global growth this year to 6%. But that estimate depends in part on the pace of the vaccine rollout.

"Anything that might effectively reduce vaccine availability is obviously not good news," said May of Oxford Economics.

The vaccine "is still usable for the most vulnerable sections of the population," he noted. But coupled with supply shortages, new restrictions could complicate the recovery in countries where AstraZeneca's vaccine is central to pandemic exit strategies, May said.

Indiana Coronavirus Cases

Data is updated nightly.

Cases: 733591

Reported Deaths: 13466
CountyCasesDeaths
Marion1003871748
Lake54020975
Allen40829679
St. Joseph35898552
Hamilton35735408
Elkhart28745442
Tippecanoe22432219
Vanderburgh22342397
Porter18871310
Johnson18028381
Hendricks17283315
Clark13015191
Madison12725339
Vigo12482248
LaPorte12011214
Monroe11928170
Delaware10726187
Howard9959218
Kosciusko9451117
Hancock8325142
Bartholomew8085156
Warrick7792155
Floyd7677178
Grant7080174
Wayne7064199
Boone6722101
Morgan6596139
Dubois6162117
Marshall6083112
Cass5839105
Dearborn582178
Henry5767104
Noble563684
Jackson502773
Shelby493696
Lawrence4571120
Harrison436372
Gibson436292
DeKalb429685
Clinton428153
Montgomery425389
Whitley397439
Huntington393380
Steuben390057
Miami382668
Knox372690
Jasper370148
Putnam362360
Wabash354980
Adams341955
Ripley340270
Jefferson331581
White315654
Daviess298299
Wells291981
Decatur285692
Fayette281662
Greene280085
Posey271933
LaGrange268370
Scott267254
Clay260647
Washington241832
Randolph241481
Spencer232631
Jennings230649
Starke217854
Fountain213246
Sullivan212142
Owen202156
Jay196730
Fulton195640
Carroll189620
Orange184154
Perry184037
Rush173725
Vermillion169743
Franklin168435
Tipton163045
Parke146616
Blackford135132
Pike135134
Pulaski117145
Newton108334
Brown102641
Crawford101315
Benton99014
Martin89515
Warren82415
Switzerland7938
Union71110
Ohio57111
Unassigned0417

Ohio Coronavirus Cases

Data is updated nightly.

Cases: 1089357

Reported Deaths: 19528
CountyCasesDeaths
Franklin1265611406
Cuyahoga1129542134
Hamilton803281211
Montgomery517261015
Summit47483955
Lucas42491792
Butler38487585
Stark32544909
Lorain25135486
Warren24359300
Mahoning21735588
Lake20791371
Clermont19844240
Delaware18582133
Licking16470212
Fairfield16284200
Trumbull16141468
Medina15341266
Greene15128244
Clark14062299
Wood13153189
Portage12930206
Allen11713232
Richland11414199
Miami10706220
Wayne8900214
Columbiana8859229
Muskingum8824133
Pickaway8589121
Marion8553136
Tuscarawas8500245
Erie7937155
Hancock6935128
Ashtabula6871172
Ross6871156
Geauga6724148
Scioto6431102
Belmont5960168
Union572948
Lawrence5583102
Jefferson5566151
Huron5453120
Darke5372126
Sandusky5369122
Seneca5305122
Washington5213109
Athens520458
Auglaize494586
Mercer481185
Shelby470193
Knox4506110
Madison438263
Putnam4297101
Fulton425969
Ashland425190
Defiance423997
Crawford3989107
Brown396657
Logan383076
Preble381098
Clinton373863
Ottawa368181
Highland356262
Williams342575
Champaign334658
Guernsey317353
Jackson313752
Perry295750
Morrow286839
Fayette282950
Hardin271564
Henry270266
Coshocton265657
Holmes2621101
Van Wert243963
Adams239553
Pike238034
Gallia236449
Wyandot232055
Hocking216062
Carroll192148
Paulding173940
Meigs145240
Noble133737
Monroe132542
Harrison109237
Morgan108523
Vinton84215
Unassigned02
Fort Wayne
Cloudy
65° wxIcon
Hi: 70° Lo: 44°
Feels Like: 65°
Angola
Cloudy
61° wxIcon
Hi: 70° Lo: 43°
Feels Like: 61°
Huntington
Cloudy
63° wxIcon
Hi: 71° Lo: 42°
Feels Like: 63°
Decatur
Cloudy
65° wxIcon
Hi: 71° Lo: 45°
Feels Like: 65°
Van Wert
Cloudy
68° wxIcon
Hi: 72° Lo: 45°
Feels Like: 68°
Isolated rain showers are possible late Saturday night into early Sunday morning. Most of Sunday will be dry and warm, but one or two pop-up showers possible Sunday afternoon.
WFFT Radar
WFFT Temperatures
WFFT National

Community Events